New molecular entity
Development and Regulatory status
Phase III Clinical Trials
CM 4612 is based on a technology platform which allows enzymes to be encapsulated and then released in the small intestine of patients who have a protein digestion deficiency.
In 2012-13 there were 513 admissions for childhood autism in England, resulting in 20,280 bed days and 545 finished consultant episodes.